Letter to the Editor: Finerenone and proteinuria in diabetic kidney disease
Vaia D Raikou, Sotiris Gavriil · 2026
Read Letter to the Editor: Finerenone and proteinuria in diabetic kidney disease by Vaia D Raikou, Sotiris Gavriil (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13491211.txt.
Description
Vaia Raikou and Sotiris Gavriil write a letter on finerenone, a drug used to cut protein loss in diabetic kidney disease. Their 2026 letter responds to a study linking bigger drops in urine protein to higher starting levels. Finerenone blocks a hormone receptor and calms kidney inflammation and scarring.
Responses to the drug vary widely between patients, the writers note. Some keep leaking protein despite full standard therapy and stay at high risk for kidney and heart events. New biology, such as histone lactylation, may help explain the stubborn cases. The letter calls for combined therapy, healthy lifestyle support, and long-term studies using gene and protein data to sort out the mechanisms.
Catalog record
| CREATOR | Vaia D Raikou, Sotiris Gavriil |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 8 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |